Mario Balsa, Medical Oncology Resident at Catalan Institute of Oncology (ICO), shared a post on X:
“A must-read for residents!
A timely review in Frontiers – Immunology dives into antibody-based strategies for HCC.
- ICIs (PD-1/L1, CTLA-4), bispecifics, ADCs
- Explores mechanisms: immune modulation, angiogenesis inhibition, cytotoxicity
- Key challenges: heterogeneity, resistance, irAEs
When it comes to HCC, antibody therapies aren’t just promising — they’re raising the bar(y)er.”
Title: Antibody treatment of hepatocellular carcinoma: a review of current and emerging approaches
Authors: Sherif A. El-Kafrawy, Mostafa S. Elkafrawy, Esam I. Azhar, Anwaar Saeed, Ashraf A. Tabll
Read the Full Article on Frontiers – Immunology
More posts featuring Mario Balsa.